Publication | Open Access
Phase I dose‐escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
13
Citations
23
References
2019
Year
The pediatric MTD/dose for further development was identified. There were no unexpected safety or PK findings; limited antitumor/antileukemic activity was demonstrated.
| Year | Citations | |
|---|---|---|
Page 1
Page 1